POTS Medication Guide
Filter by POTS subtype and treatment line to find the right medication for your patient. Includes mechanism, dosing, evidence grade, and key cautions for each drug.
Prescribing note: Several medications used in POTS are off-label. Always discuss with the patient, document informed consent, and base clinical decisions on individual assessment. Non-pharmacological measures should be optimised before adding medication.
Filter by Subtype
Filter by Treatment Line
Showing 10 of 10 options
Salt & Fluid Loading
8–10g salt/day + 2–3L fluid/day
Mechanism: Increases plasma volume — addresses hypovolaemia underlying most POTS subtypes
Key Points
- Always first-line before any medication
- Electrolyte drinks helpful during activity
- Salt tablets (1–2g TDS) if dietary increase insufficient
- Review with dietitian for sustained adherence
Cautions
- Contraindicated in hypertension, heart failure, renal impairment — check BP and U&E first
Fludrocortisone
0.05–0.2 mg daily (morning)
Mechanism: Mineralocorticoid — increases renal sodium and water retention, expanding plasma volume
Key Points
- Start at 0.05mg daily, titrate slowly
- Takes 2–4 weeks for full effect
- Monitor BP and serum potassium
- Most effective in hypovolaemic and neuropathic subtypes
Cautions
- Avoid in hyperadrenergic POTS — worsens hypertension
- Monitor for ankle oedema, supine hypertension, hypokalaemia
- Avoid in pregnancy (category C)
Propranolol (low dose)
10–40 mg TDS/QDS (NOT high dose)
Mechanism: Non-selective beta-blocker — blunts tachycardia response; most effective in hyperadrenergic subtype
Key Points
- Low dose ONLY — high doses paradoxically worsen POTS via reduced cardiac output
- Take 30–60 min before anticipated activity
- Particularly effective when palpitations are the dominant symptom
- IV propranolol superior to oral in trials but oral widely used
Cautions
- Contraindicated in asthma and reactive airways disease
- May worsen fatigue and exercise tolerance
- Do not stop abruptly — taper over 2 weeks
Ivabradine
2.5–7.5 mg BD (with meals)
Mechanism: Selective If-channel blocker — reduces sinus rate without affecting contractility or BP
Key Points
- Preferred over beta-blockers when fatigue or BP effects are a concern
- Does not reduce cardiac output — better tolerated in exercise
- Growing evidence base in POTS specifically
- Useful when beta-blockers not tolerated
Cautions
- Off-label use for POTS — document and obtain consent
- Contraindicated in acute/decompensated heart failure, sick sinus, severe hepatic impairment
- Bradycardia risk — monitor resting HR
- Not in pregnancy
Midodrine
2.5–10 mg TDS (last dose by 6 pm)
Mechanism: Alpha-1 adrenergic agonist — peripheral vasoconstriction, reduces venous pooling in lower limbs
Key Points
- Take 30–45 min before standing/activity
- Three times daily during waking hours — final dose before 6 pm to avoid supine hypertension
- Most effective for neuropathic POTS with prominent pooling
- Combination with fludrocortisone often synergistic
Cautions
- NEVER take within 4 hours of lying down — risk of supine hypertension
- Contraindicated in supine hypertension, severe heart disease, urinary retention, thyrotoxicosis
- Side effects: piloerection, scalp tingling, urinary hesitancy
Pyridostigmine
30–60 mg BD–TDS
Mechanism: Acetylcholinesterase inhibitor — enhances ganglionic autonomic transmission, improves peripheral vasoconstriction
Key Points
- One of few drugs with RCT evidence specifically in POTS (Singer et al.)
- Particularly useful in neuropathic and autoimmune subtypes
- Enhances parasympathetic and sympathetic tone
- Can be combined with other agents
Cautions
- GI side effects common (nausea, diarrhoea, abdominal cramps) — take with food
- Avoid in asthma, bowel obstruction, urinary obstruction
- Not in pregnancy
Clonidine
0.05–0.2 mg BD
Mechanism: Central alpha-2 agonist — reduces sympathetic outflow, specifically useful in hyperadrenergic subtype
Key Points
- Consider specifically when standing noradrenaline is elevated (>600 pg/mL)
- Reduces sympathetic tone centrally
- Use with caution alongside other antihypertensives
Cautions
- Sedation (often significant), dry mouth, constipation
- Rebound hypertension on abrupt withdrawal — always taper
- Not first choice unless hyperadrenergic subtype confirmed
SSRIs / SNRIs
Various (standard antidepressant doses)
Mechanism: Serotonergic modulation of autonomic tone; treats comorbid anxiety and depression
Key Points
- Consider when anxiety or depression is a prominent comorbidity
- Some evidence in post-COVID / autoimmune POTS
- May initially worsen tachycardia — start low
- Fluoxetine used in some pilot studies
Cautions
- Monitor HR and BP closely on initiation
- QTc prolongation risk — check ECG if combining with other QT-affecting drugs
Low-Dose Naltrexone (LDN)
1.5–4.5 mg at night
Mechanism: Immunomodulatory at low doses — emerging evidence in autoimmune and post-COVID POTS
Key Points
- Specialist / research centre use only
- Most relevant for autoimmune POTS and post-COVID phenotype
- Off-label — limited but growing evidence base
- Anecdotal reports of significant improvement in long COVID POTS
Cautions
- Strictly off-label — document informed consent
- Avoid in opioid dependence or concurrent opioid analgesia
- Limited safety data in POTS specifically
Intravenous (IV) Saline
1–2L normal saline infusion
Mechanism: Acute plasma volume expansion — rapid symptom relief in severe/refractory episodes
Key Points
- For acute severe flares or pre/post-procedure
- Not sustainable as long-term management
- PICC line home infusion used in selected severe cases in specialist centres
Cautions
- Risk of fluid overload, electrolyte disturbance
- Home infusion requires specialist supervision
- Not a substitute for oral hydration strategies
Before prescribing any medication
Non-pharmacological measures (salt/fluid loading, compression, exercise rehabilitation) must be optimised first. Most patients with POTS will improve significantly with lifestyle measures alone. Medication is additive, not a substitute.
For the full management protocol including the Levine Exercise Programme and stepwise treatment algorithm, see the Management page.